UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/523,842	06/13/2005	Ryuji Ueno	265678US0PCT	4376
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER	
			FAY, ZOHREH A	
			ART UNIT	PAPER NUMBER
			1618	
			•	
•			NOTIFICATION DATE	DELIVERY MODE
	·	- 10	08/14/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

		Application No.	Applicant(s)				
		10/523,842	ÚENO, RYUJI				
	Office Action Summary	Examiner	Art Unit				
		Zohreh A. Fay	1618				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SH WHIC - External afternal	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAnsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing end patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on <u>07 Ma</u>	<u>ay 2007</u> .					
<i>'</i> —	This action is FINAL . 2b) This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)⊠	4)⊠ Claim(s) <u>1,4-9,11,12,15-20 and 34</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.							
•	Claim(s) is/are allowed.						
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>1, 4-9, 11, 12, 15-20 and 34</u> is/are rejection	ected.					
•	Claim(s) is/are objected to.	r alastian raquiroment					
اــا(٥	Claim(s) are subject to restriction and/or	election requirement.					
Application Papers							
9)[The specification is objected to by the Examine	r.					
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form P1O-152.				
Priority u	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
	see the attached detailed Office action for a list of	or the certified copies not receive	u.				
Attachmen							
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
3) Inform	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal Pa					

Application/Control Number: 10/523,842

Art Unit: 1618

Claims 1 and 4-12 and 15-20 are presented for examination.

The amendments and remarks filed on May 7, 2007 have been received and entered.

Claims 1, 4- 12, 15-20 and 34 are rejected under Judially –created doctrine of obviousness double patenting as being unpatentable over claims 1, 3, 6 and 7 of U.S. Patent 6,872,383 for the reasons set forth in the office action of February 6, 2007.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Application/Control Number: 10/523,842

Art Unit: 1618

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 4-12 and 15-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Asakura et al. (US 5,368,865). Asakura et al. teach the use of the claimed macrolide compounds in a pharmaceutical formulation for the treatment of vernal conjunctivitis, which is an allergic conjunctivitis. See the abstract, column 10, lines 56-64. The claimed range concentration is taught in column 6, lines 30-39. The above reference differs from the claimed invention in the exact concentrations and the kit of claim 34. It would have been obvious to a person skilled in the art to use the claimed concentrations, considering that the prior art teaches the claimed range concentrations. To use a pharmaceutical composition in a pharmaceutically acceptable kit is also considered to be within the skill of the art. The written instruction on a kit does not have any patentable weight, and does not create a patentably distinct composition or a kit.

Applicant's arguments regarding the double patenting rejection have been carefully considered, but are not deemed to be persuasive. Applicant in his remarks argues that the patent 6,872,383 is related to the treatment of dry eye and not allergic conjunctivitis. The arguments are not well taken. The prior art is directed to the U.S. Patent is directed to treating an ocular disorder, which covers any ophthalmic disorder, such as allergic conjunctivitis.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 10/523,842 Page 4

Art Unit: 1618

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh A. Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on Monday to Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Z.F

